Menu Search
Equities

Immunic Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
10VA:FRA

Immunic Inc

Actions
  • Price (EUR)0.61
  • Today's Change-0.112 / -15.51%
  • Shares traded10.00k
  • 1 Year change-32.89%
  • Beta1.5660
Data delayed at least 15 minutes, as of Feb 12 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.

  • Revenue in USD (TTM)0.00
  • Net income in USD-103.05m
  • Incorporated2004
  • Employees91.00
  • Location
    Immunic Inc1200 Avenue Of The Americas, Suite 200NEW YORK 10036United StatesUSA
  • Phone+49 (8925) 007-9460
  • Fax+1 (302) 655-5049
  • Websitehttps://imux.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.